We are live on !
Find out more
Longaeva Partners Portfolio holdings
AUM
$4.58B
Turnover
75.17%
1-Year Est. Return
43.91%
This Fund
S&P 500
This Quarter Est. Return
+20.82%
1 Year Est. Return
+43.91%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.58B
AUM Growth
+$1.88B
(+69%)
Cap. Flow
+$1.03B
Cap. Flow % of AUM
Cap. Flow %
22.6%
Top 10 Holdings %
Top 10 Hldgs %
29.9%
Holding
435
New
231
Increased
47
Reduced
58
Closed
96
Avg Time Held
Equity + Options
0.1
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$101M |
| 2 |
JPMorgan Chase
JPM
|
+$79.2M |
| 3 |
Moody's
MCO
|
+$58.8M |
| 4 |
Fifth Third Bancorp
FITB
|
+$58.5M |
| 5 |
LPL Financial
LPLA
|
+$56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PNC Financial Services
PNC
|
+$68M |
| 2 |
ACM Research
ACMR
|
+$48.8M |
| 3 |
Citizens Financial Group
CFG
|
+$47.1M |
| 4 |
Vishay Intertechnology
VSH
|
+$46.3M |
| 5 |
Goldman Sachs
GS
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.82% |
| 2 | Financials | 20.39% |
| 3 | Healthcare | 17.29% |
| 4 | Industrials | 14.57% |
| 5 | Technology | 7.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Amer Sports
AS
$16.4B
| $17.6M | 0.39% |
521,473
-177,040
| -25% | -$6.2M |
2025 Q2
4 quarters
|
|
77
XPO
XPO
$21.5B
| $17.3M | 0.38% |
+84,513
| New | +$17.9M |
2026 Q2
0 quarters
|
|
78
Johnson Controls International
JCI
$87.2B
| $17.3M | 0.38% |
118,276
-30,726
| -21% | -$4.34M |
2026 Q1
1 quarter
|
|
79
On Holding
ONON
$10.9B
| $17.1M | 0.37% |
483,000
+170,000
| +54% | +$6.21M |
2026 Q1
1 quarter
|
|
80
Kinder Morgan
KMI
$76.7B
| $17.1M | 0.37% |
+534,265
| New | +$17.2M |
2026 Q2
0 quarters
|
|
81
AbbVie
ABBV
$505B
| $16.9M | 0.37% |
+67,093
| New | +$14.4M |
2026 Q2
0 quarters
|
|
82
Louisiana-Pacific
LPX
$5.16B
| $16.8M | 0.37% |
+213,511
| New | +$15.8M |
2026 Q2
0 quarters
|
|
83
Jazz Pharmaceuticals
JAZZ
$13.9B
| $16.6M | 0.36% |
+68,792
| New | +$15.1M |
2026 Q2
0 quarters
|
|
84
EPAM Systems
EPAM
$7.03B
| $16.1M | 0.35% |
+202,856
| New | +$21.4M |
2026 Q2
0 quarters
|
|
85
Enliven Therapeutics
ELVN
$3.04B
| $15.9M | 0.35% |
312,560
+199,495
| +176% | +$8.47M |
2026 Q1
1 quarter
|
|
86
Kinetik
KNTK
$4.48B
| $15.1M | 0.33% |
311,859
+859
| +0.3% | +$41.1K |
2025 Q2
4 quarters
|
|
87
Vertex Pharmaceuticals
VRTX
$133B
| $15M | 0.33% |
30,279
+5,344
| +21% | +$2.37M |
2026 Q1
1 quarter
|
|
88
State Street Financial Select Sector SPDR ETF
XLF
$51.9B
| $14.6M | 0.32% |
+272,485
| New | +$14.2M |
2026 Q2
0 quarters
|
|
89
Genius Sports
GENI
$1.69B
| $14.4M | 0.32% |
2,379,279
-1,461,866
| -38% | -$7.57M |
2025 Q4
2 quarters
|
|
90
W.W. Grainger
GWW
$63.6B
| $14.4M | 0.31% |
10,591
-676
| -6% | -$833K |
2026 Q1
1 quarter
|
|
91
BridgeBio Pharma
BBIO
$13.4B
| $14M | 0.31% |
+187,863
| New | +$13.2M |
2026 Q2
0 quarters
|
|
92
Arxis Inc
ARXS
$22.3B
| $13.8M | 0.3% |
+300,155
| New | +$11.7M |
2026 Q2
0 quarters
|
|
93
Block Inc
XYZ
$45.9B
| $13.5M | 0.3% |
+177,808
| New | +$12.5M |
2026 Q2
0 quarters
|
|
94
Contineum Therapeutics
CTNM
$313M
| $13.3M | 0.29% |
812,757
+80,669
| +11% | +$1.06M |
2025 Q4
2 quarters
|
|
95
Home Depot
HD
$319B
| $13.1M | 0.29% |
37,235
-8,765
| -19% | -$2.85M |
2026 Q1
1 quarter
|
|
96
Tango Therapeutics
TNGX
$3.94B
| $13M | 0.28% |
+414,902
| New | +$10.3M |
2026 Q2
0 quarters
|
|
97
Waystar Holding Corp
WAY
$5.53B
| $13M | 0.28% |
+631,729
| New | +$13.3M |
2026 Q2
0 quarters
|
|
98
Wyndham Hotels & Resorts
WH
$5.37B
| $12.7M | 0.28% |
151,006
+71,306
| +89% | +$5.91M |
2025 Q4
2 quarters
|
|
99
Ares Management
ARES
$27.8B
| $12.6M | 0.27% |
113,039
+109,964
| +3,576% | +$13.2M |
2025 Q4
2 quarters
|
|
100
Haemonetics
HAE
$5.39B
| $12.3M | 0.27% |
+163,822
| New | +$10.5M |
2026 Q2
0 quarters
|
|
Similar funds
BWA
Longaeva Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Longaeva Partners held 435 positions worth $4.58B, up 69% from $2.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Longaeva Partners deployed $1.03B of net new capital in Q2 2026, opening 231 new positions and adding to 47 existing holdings. Its largest new stake was SpaceX: 596,829 shares worth $102M.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was ACM Research, an estimated $48.8M trimmed.
- Longaeva Partners's largest Q2 2026 buy was SpaceX: 596,829 shares worth $102M.
- Longaeva Partners added most to Mettler-Toledo International in Q2 2026, an estimated $39.4M increase.
- Longaeva Partners's biggest Q2 2026 reduction was ACM Research, cutting an estimated $48.8M.
- Longaeva Partners fully exited PNC Financial Services in Q2 2026, selling an estimated $68M.
- Longaeva Partners's ten largest holdings make up 30% of its $4.58B portfolio in Q2 2026.
- Longaeva Partners opened 231 new positions and closed 96 in Q2 2026.
- Longaeva Partners's portfolio value rose 69% quarter-over-quarter to $4.58B.
Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.